Will New Ratings Coverage by Piper Jaffray Help Aimmune Therapeutics (AIMT) Stock This Week?

May 18, 2018 - By Susan Price

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

Why Has Piper Jaffray Given Aimmune Therapeutics (AIMT) a $60.0000 Price Target

Analysts at Piper Jaffray started coverage on shares of Aimmune Therapeutics (AIMT) in an analyst report revealed to clients and investors on Friday morning. The financial company set Buy rating on the $1.74B market cap company.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Coverage

Among 8 analysts covering Aimmune Therapeutics (AIMT), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics has $80.0 highest and $30.0 lowest target. $59.25’s average target is 97.43% above currents $30.01 stock price. Aimmune Therapeutics had 22 analyst reports since November 20, 2017 according to SRatingsIntel. Wedbush maintained Aimmune Therapeutics, Inc. (NASDAQ:AIMT) on Friday, February 23 with “Buy” rating. The firm earned “Buy” rating on Monday, November 20 by Roth Capital. As per Tuesday, December 5, the company rating was maintained by Piper Jaffray. Roth Capital maintained it with “Buy” rating and $80.0 target in Monday, March 5 report. The firm earned “Buy” rating on Tuesday, February 20 by Cantor Fitzgerald. Roth Capital maintained Aimmune Therapeutics, Inc. (NASDAQ:AIMT) on Tuesday, February 20 with “Buy” rating. The stock has “Buy” rating by Credit Suisse on Tuesday, February 27. The stock has “Buy” rating by Wedbush on Monday, February 12. The stock has “Buy” rating by Cantor Fitzgerald on Sunday, March 25. Piper Jaffray maintained it with “Buy” rating and $62.0 target in Tuesday, February 27 report.

The stock increased 0.17% or $0.05 during the last trading session, reaching $30.01. About 288,238 shares traded. Aimmune Therapeutics, Inc. (AIMT) has risen 29.28% since May 18, 2017 and is uptrending. It has outperformed by 17.73% the S&P500.

Analysts await Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report earnings on August, 14. They expect $-0.68 earnings per share, down 4.62 % or $0.03 from last year’s $-0.65 per share. After $-0.92 actual earnings per share reported by Aimmune Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.09 % EPS growth.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.74 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

More notable recent Aimmune Therapeutics, Inc. (NASDAQ:AIMT) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 18, 2018, also Seekingalpha.com with their article: “Backing Blackstone For A Decade – Cramer’s Lightning Round (4/23/18)” published on April 24, 2018, Businesswire.com published: “Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical …” on May 15, 2018. More interesting news about Aimmune Therapeutics, Inc. (NASDAQ:AIMT) were released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: Aimmune, Anadarko, Carrizo, Mastercard, PayPal, Spotify, Visa and More” published on May 18, 2018 as well as Streetinsider.com‘s news article titled: “Piper Jaffray Assumes Aimmune Therapeutics (AIMT) at Overweight” with publication date: May 18, 2018.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: